Physician profile
Dorian Blake
NPI 1396233490
$4,455.13
in general payments reported to CMS, 2019-2025
11 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.73 · 2023: $704 · 2024: $1,439 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Consulting Fee: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.40 |
| Consulting Fee | $840.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,157.47 | 2023-2025 | |
| Pfizer INC. | $1,382.25 | 2023-2025 | |
| Lundbeck LLC | $405.00 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $248.57 | 2023-2025 | Ajovy, Austedo Xr |
| Scilex Pharmaceuticals INC. | $85.88 | 2024-2025 | |
| Lilly USA, LLC | $73.77 | 2024 | Emgality |
| Axsome Therapeutics, INC. | $29.41 | 2025 | Symbravo |
| Harmony Biosciences LLC | $22.46 | 2024 | |
| Bioventus LLC | $18.73 | 2021 | |
| Impel Pharmaceuticals INC. | $16.81 | 2023 | Trudhesa |
| Kowa Pharmaceuticals America, INC. | $14.78 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorian Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.